Back to search results

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

IsraelRecruitingPHASE3

Conditions

Secondary Progressive Multiple Sclerosis (SPMS)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Alabama Neurology Associates PC, Birmingham, Alabama, United States

    Contact: Study coordinator (Virginia Weinacker) · gweinacker@alaneuro.com · +1 205 803 2210
    Contact: Principal Investigator (Emily Sherill Riser)

  • Ctr for Neurology and Spine, Phoenix, Arizona, United States

    Contact: Study coordinator (Madison Turner) · madison@centerforneurologyandspine.com
    Contact: Principal Investigator (Leslie Zuniga)

  • AZ Integrated Neuro and Spine, Phoenix, Arizona, United States

    Contact: Study coordinator (Nicole Hank) · nhank@prcresearcheducation.com
    Contact: Principal Investigator (Barry Hendin)

  • Center for Neurosciences, Tucson, Arizona, United States

    Contact: Study coordinator (Lisa Alvarez) · lalvarez@neurotucson.com · +1 520 320 2147
    Contact: Principal Investigator (Francisco Valdivia)

  • Fullerton Neuro and Headache Ctr, Fullerton, California, United States

    Contact: Study coordinator (Alexandra Vasquez) · avasquez@fullertonneuro.net · +1 714 738 0800
    Contact: Principal Investigator (Jack H Florin)

  • Regina Berkovich MD PhD Inc, West Hollywood, California, United States

    Contact: Study coordinator (Divya Venkataramu) · venkataramu.neuro@gmail.com · +1 310 493 4715
    Contact: Principal Investigator (Regina Berkovich)

  • UC Health Neuroscience Ctr, Aurora, Colorado, United States

    Contact: Study coordinator (Isabel Adkisson) · isabel.adkisson@cuanschutz.edu
    Contact: Principal Investigator (Enrique Alvarez)

  • Georgetown University Hospital, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Grace Inserra) · gi90@georgetown.edu · +1 202 444 8830
    Contact: Principal Investigator (Faria Amjad)

  • Medstar Washington Hosp Ctr, Washington D.C., District of Columbia, United States

    Contact: Study coordinator (Anu Bhooshan) · anu.r.bhooshan@medstar.net · +1 202 877 7000
    Contact: Principal Investigator (Brian Barry)

  • Neurology of Central FL Res Ctr, Altamonte Springs, Florida, United States

    Contact: Study coordinator (Adiana Perez) · adiresearchcfl@gmail.com · +1 407 790 4990
    Contact: Principal Investigator (Alicia V Cabrera)

  • UF Health Cancer Center, Gainesville, Florida, United States

    Contact: Study coordinator (Kyle Rizer) · kyle.rizer@neurology.ufl.edu · +1 352 733 2412
    Contact: Principal Investigator (Torge Rempe)

  • Homestead Assoc In Research Inc, Homestead, Florida, United States

    Contact: Study coordinator (Daydene Ordaz) · dordaz@associatesinresearch.com · 13052460873
    Contact: Principal Investigator (Angel Carrasco)

  • Neurology Associates PA, Maitland, Florida, United States

    Contact: Study coordinator (Kelly Holley) · admin@naparesearch.com · +1 407 647 5996
    Contact: Principal Investigator (William David Honeycutt)

  • Miami NS Ins Baptist Health S FL, Miami, Florida, United States

    Contact: Study coordinator (Sukie Hernandez) · sukie.hernandez@baptisthealth.net
    Contact: Principal Investigator (Luis Compres Brugal)

  • Aqualane Clinical Research, Naples, Florida, United States

    Contact: Study coordinator (Taylor Kerskie) · taylor@aqualaneresearch.com · +1 239 434 0332
    Contact: Principal Investigator (Matthew J Baker)

  • Orlando Health Clinical Trials, Orlando, Florida, United States

    Contact: Study coordinator (Charlene Carlo) · Charlene.carlo@orlandohealth.com · +1 321 841 3686
    Contact: Principal Investigator (Amparo Gutierrez)

  • Comprehensive Neurology Clinic, Orlando, Florida, United States

    Contact: Study coordinator (Elliuz Leal) · elealcrc@gmail.com · +1 407 913 9120
    Contact: Principal Investigator (Refaat El-Said)

  • Neurology Associates of Ormond Beach, Ormond Beach, Florida, United States

    Contact: Study coordinator (Heather Schutz) · hschutz@naobresearch.com · +1 386 676 6340
    Contact: Principal Investigator (James Scott)

  • Axiom Brain Health, Tampa, Florida, United States

    Contact: Study coordinator (Jennifer Fornes) · jfornes@axiombrainhealth.com
    Contact: Principal Investigator (Mark Cascione)

  • University Of South Florida, Tampa, Florida, United States

    Contact: Study coordinator (Eduardo Sucre) · eduardosucre@usf.edu · +1 813 974 6378
    Contact: Principal Investigator (John Ciotti)

  • Joi Life Wellness Group LLC, Smyrna, Georgia, United States

    Contact: Study coordinator (Carmel Ibeawuchi) · cibeawuchi@msm.edu
    Contact: Principal Investigator (Mitzi Joi Williams)

  • Hawaii Pacific Neuroscience LLC, Honolulu, Hawaii, United States

    Contact: Study coordinator (Gina McNarney) · gmcnarney@hawaiineuroscience.com · +1 808 261 4476
    Contact: Principal Investigator (Natalia Gonzalez-Caldito)

  • Northwestern Memorial Hospital, Chicago, Illinois, United States

    Contact: Study coordinator (Caroline Gebczak) · caroline.Gebczak@northwestern.edu
    Contact: Principal Investigator (Edith Graham)

  • University of Kansas Hospital, Kansas City, Kansas, United States

    Contact: Study coordinator (Sarah Razor) · sbellis2@kumc.edu · +1 913 945 5059
    Contact: Principal Investigator (Sharon Lynch)

  • Mid Atlantic Epilepsy and Sleep Ctr, Bethesda, Maryland, United States

    Contact: Study coordinator (Salman Hashmi) · hashmis@epilepsydc.com
    Contact: Principal Investigator (Jonathan Ross)

  • Neuro Institute of New England P C, Foxborough, Massachusetts, United States

    Contact: Study coordinator (Jillian Pellegrini) · jpellegrini@neurocenterne.com · +1 781 551 5812
    Contact: Principal Investigator (Salvatore Napoli)

  • Elliot Lewis MS Center, Wellesley, Massachusetts, United States

    Contact: Study coordinator (Isabelle Messina) · isabellemessina@elliotlewisms.org · +1 781 591 8300
    Contact: Principal Investigator (Andrew Bouley)

  • U Mass Memorial Medical Center, Worchester, Massachusetts, United States

    Contact: Study coordinator (Rafael Fernandes) · rafael.fernandes@umassmed.edu · +1 508 856 5073
    Contact: Principal Investigator (Carolina Ionete)

  • Michigan Institute of Neurological, Farmington Hills, Michigan, United States

    Contact: Study coordinator (Dianna Rogan) · drogan@mindonline.com · +1 248 553 0010
    Contact: Principal Investigator (Martin Belkin)

  • University of New Mexico Hospital, Albuquerque, New Mexico, United States

    Contact: Study coordinator (Sophia Pearson) · SMPearson@salud.unm.edu · +1 505 272 4550
    Contact: Principal Investigator (Clotilde Hainline)

  • Premier Neurology, Greenville, South Carolina, United States

    Contact: Study coordinator (Mallory Gedeon) · mallory.g@premier-neuro.com
    Contact: Principal Investigator (Mary Denise Hughes)

  • Neurology Clinic PC, Cordova, Tennessee, United States

    Contact: Study coordinator (Ye Liu) · yliu@neuroclinic.org · +1 901 866 9252
    Contact: Principal Investigator (Lee Stein)

  • Neurology Consultants Of Dallas PA, Dallas, Texas, United States

    Contact: Study coordinator (Sarah Pelfrey) · Spelfrey@neurologydallas.com
    Contact: Principal Investigator (Adnan Subei)

  • Saturn Research Solution, Plano, Texas, United States

    Contact: Study coordinator (Maxine Fligg) · mfligg@saturnclinical.com
    Contact: Principal Investigator (Annette Okai)

  • University of Washington MS Clinic, Seattle, Washington, United States

    Contact: Study coordinator (Elisa McGee) · emcgee@uw.edu · +1 206 598 3344
    Contact: Principal Investigator (Gloria von Geldern)

  • Citta Clinical Research, Spokane, Washington, United States

    Contact: Study coordinator (Jill Ciccarello) · jciccarello@cittaclinicalresearch.com
    Contact: Principal Investigator (Michael Coats)

  • Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina

  • Novartis Investigative Site, Buenos Aires, Buenos Aires F.D., Argentina

  • Novartis Investigative Site, Bombal, Mendoza Province, Argentina

  • Novartis Investigative Site, Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site, Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site, Santiago del Estero, Santiago del Estero Province, Argentina

  • Novartis Investigative Site, San Miguel de, Tucumán Province, Argentina

  • Novartis Investigative Site, Buenos Aires, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, CABA, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, Caba, Argentina

  • Novartis Investigative Site, Kogarah, New South Wales, Australia

  • Novartis Investigative Site, New Lambton Heights, New South Wales, Australia

  • Novartis Investigative Site, Westmead, New South Wales, Australia

  • Novartis Investigative Site, Clayton, Victoria, Australia

  • Novartis Investigative Site, Heidelberg, Victoria, Australia

  • Novartis Investigative Site, Murdoch, Western Australia, Australia

  • Novartis Investigative Site, Southport, Australia

  • Novartis Investigative Site, Innsbruck, Tyrol, Austria

  • Novartis Investigative Site, Linz, Upper Austria, Austria

  • Novartis Investigative Site, Linz, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Leuven, Vlaams Brabant, Belgium

  • Novartis Investigative Site, Roeselare, West-Vlaanderen, Belgium

  • Novartis Investigative Site, Bonheiden, Belgium

  • Novartis Investigative Site, Brussels, Belgium

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Santo André, São Paulo, Brazil

  • Novartis Investigative Site, Pleven, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Sofia, Bulgaria

  • Novartis Investigative Site, Vancouver, British Columbia, Canada

  • Novartis Investigative Site, Halifax, Nova Scotia, Canada

  • Novartis Investigative Site, Ottawa, Ontario, Canada

  • Novartis Investigative Site, Lévis, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Montreal, Quebec, Canada

  • Novartis Investigative Site, Québec, Quebec, Canada

  • Novartis Investigative Site, Sherbrooke, Quebec, Canada

  • Novartis Investigative Site, Guangzhou, Guangdong, China

  • Novartis Investigative Site, Zhengzhou, Henan, China

  • Novartis Investigative Site, Wuhan, Hubei, China

  • Novartis Investigative Site, Wuhan, Hubei, China

  • Novartis Investigative Site, Hohhot, Inner Mongolia, China

  • Novartis Investigative Site, Suzhou, Jiangsu, China

  • Novartis Investigative Site, Changchun, Jilin, China

  • Novartis Investigative Site, Shenyang, Liaoning, China

  • Novartis Investigative Site, Yinchuan, Ningxia, China

  • Novartis Investigative Site, Xianyang, Shaanxi, China

  • Novartis Investigative Site, Taiyuan, Shanxi, China

  • Novartis Investigative Site, Hangzhou, Zhejiang, China

  • Novartis Investigative Site, Hangzhou, Zhejiang, China

  • Novartis Investigative Site, Wenzhou, Zhejiang, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Beijing, China

  • Novartis Investigative Site, Chongqing, China

  • Novartis Investigative Site, Shanghai, China

  • Novartis Investigative Site, Tianjin, China

  • Novartis Investigative Site, Barranquilla, Atlántico, Colombia

  • Novartis Investigative Site, Bogotá, Colombia

  • Novartis Investigative Site, Medellín, Colombia

  • Novartis Investigative Site, Medellín, Colombia

  • Novartis Investigative Site, Varaždin, Croatia

  • Novartis Investigative Site, Brno, Czechia

  • Novartis Investigative Site, Hradec Králové, Czechia

  • Novartis Investigative Site, Jihlava, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Teplice, Czechia

  • Novartis Investigative Site, Aarhus N, Denmark

  • Novartis Investigative Site, Esbjerg, Denmark

  • Novartis Investigative Site, Tallinn, Estonia

  • Novartis Investigative Site, Limoges, Haute Vienne, France

  • Novartis Investigative Site, Ajaccio, France

  • Novartis Investigative Site, Amiens, France

  • Novartis Investigative Site, Clermont-Ferrand, France

  • Novartis Investigative Site, Gonesse, France

  • Novartis Investigative Site, Grenoble, France

  • Novartis Investigative Site, Lille, France

  • Novartis Investigative Site, Lille, France

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Nancy, France

  • Novartis Investigative Site, Nice, France

  • Novartis Investigative Site, Nîmes, France

  • Novartis Investigative Site, Orsay, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Poitiers, France

  • Novartis Investigative Site, Rennes, France

  • Novartis Investigative Site, Rouen, France

  • Novartis Investigative Site, Strasbourg, France

  • Novartis Investigative Site, Toulouse, France

  • Novartis Investigative Site, Tours, France

  • Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site, Mannheim, Baden-Wurttemberg, Germany

  • Novartis Investigative Site, Munich, Bavaria, Germany

  • Novartis Investigative Site, Unterhaching, Bavaria, Germany

  • Novartis Investigative Site, Halle, Saxony-Anhalt, Germany

  • Novartis Investigative Site, Erfurt, Germany

  • Novartis Investigative Site, Giessen, Germany

  • Novartis Investigative Site, Greifswald, Germany

  • Novartis Investigative Site, Heidelberg, Germany

  • Novartis Investigative Site, Itzehoe, Germany

  • Novartis Investigative Site, Tübingen, Germany

  • Novartis Investigative Site, Athens, Greece

  • Novartis Investigative Site, Chaïdári, Greece

  • Novartis Investigative Site, Ioannina, Greece

  • Novartis Investigative Site, Budapest, Hungary

  • Novartis Investigative Site, Budapest, Hungary

  • Novartis Investigative Site, Budapest, Hungary

  • Novartis Investigative Site, Kistarcsa, Hungary

  • Novartis Investigative Site, Gurugram, Haryana, India

  • Novartis Investigative Site, Mangalore, Karnataka, India

  • Novartis Investigative Site, Kochi, Kerala, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, New Delhi, National Capital Territory of Delhi, India

  • Novartis Investigative Site, Chandigarh, Punjab, India

  • Novartis Investigative Site, Vellore, Tamil Nadu, India

  • Novartis Investigative Site, Hyderabad, Telangana, India

  • Novartis Investigative Site, Ashkelon, Israel

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Jerusalem, Israel

  • Novartis Investigative Site, Ramat Gan, Israel

  • Novartis Investigative Site, Rehovot, Israel

  • Novartis Investigative Site, Tel Aviv, Israel

  • Novartis Investigative Site, Ẕerifin, Israel

  • Novartis Investigative Site, Bergamo, BG, Italy

  • Novartis Investigative Site, Foggia, FG, Italy

  • Novartis Investigative Site, Pozzilli, IS, Italy

  • Novartis Investigative Site, Pavia, PV, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Kaunas, Lithuania

  • Novartis Investigative Site, Chihuahua City, Chihuahua, Mexico

  • Novartis Investigative Site, Benito Juárez, Mexico City, Mexico

  • Novartis Investigative Site, San Luis Potosí City, Mexico

  • Novartis Investigative Site, Arnhem, Gelderland, Netherlands

  • Novartis Investigative Site, 's-Hertogenbosch, North Brabant, Netherlands

  • Novartis Investigative Site, Leiden, Netherlands

  • Novartis Investigative Site, Krakow, Lesser Poland Voivodeship, Poland

  • Novartis Investigative Site, Krakow, Poland, Poland

  • Novartis Investigative Site, Bydgoszcz, Woj Kujawsko Pomorskie, Poland

  • Novartis Investigative Site, Chojnice, Poland

  • Novartis Investigative Site, Katowice, Poland

  • Novartis Investigative Site, Katowice, Poland

  • Novartis Investigative Site, Lodz, Poland

  • Novartis Investigative Site, Lublin, Poland

  • Novartis Investigative Site, Rzeszów, Poland

  • Novartis Investigative Site, Skorzewo, Poland

  • Novartis Investigative Site, Warsaw, Poland

  • Novartis Investigative Site, Zabrze, Poland

  • Novartis Investigative Site, Żory, Poland

  • Novartis Investigative Site, Braga, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Lisbon, Portugal

  • Novartis Investigative Site, Porto, Portugal

  • Novartis Investigative Site, Constanța, ROM, Romania

  • Novartis Investigative Site, Bucharest, Romania

  • Novartis Investigative Site, Campulung Muscel, Romania

  • Novartis Investigative Site, Trnava, Slovakia, Slovakia

  • Novartis Investigative Site, Bratislava, Slovakia

  • Novartis Investigative Site, Komárno, Slovakia

  • Novartis Investigative Site, Nitra, Slovakia

  • Novartis Investigative Site, Cape Town, Western Cape, South Africa

  • Novartis Investigative Site, Barcelona, Barcelona, Spain

  • Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site, Jerez de la Frontera, Cadiz, Spain

  • Novartis Investigative Site, Logroño, La Rioja, Spain

  • Novartis Investigative Site, Pozuelo de Alarcón, Madrid, Spain

  • Novartis Investigative Site, Torrejón de Ardoz, Madrid, Spain

  • Novartis Investigative Site, El Palmar, Murcia, Spain

  • Novartis Investigative Site, Castilleja de la Cuesta, Sevilla, Spain

  • Novartis Investigative Site, Valencia, Valencia, Spain

  • Novartis Investigative Site, Barakaldo, Vizcaya, Spain

  • Novartis Investigative Site, Alicante, Spain

  • Novartis Investigative Site, Las Palmas GC, Spain

  • Novartis Investigative Site, Lleida, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Málaga, Spain

  • Novartis Investigative Site, Salamanca, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Bern, Switzerland

  • Novartis Investigative Site, Lausanne, Switzerland

  • Novartis Investigative Site, Brighton, East Sussex, United Kingdom

  • Novartis Investigative Site, Romford, Essex, United Kingdom

  • Novartis Investigative Site, Coventry, United Kingdom

  • Novartis Investigative Site, Glasgow, United Kingdom

  • Novartis Investigative Site, Leeds, United Kingdom

  • Novartis Investigative Site, London, United Kingdom

  • Novartis Investigative Site, Nottingham, United Kingdom

View source on ClinicalTrials.gov(opens in a new tab)